These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38682328)

  • 1. Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial.
    Zaeri H; Omidvar S; Servatian N; Arefnia S; Khademolreza N; Amini H; Taghavi B; Hashemipour M; Eshraghi P; Ghasemi M; Ghergherehchi R; Maleki E; Moravej H; Noorian S; Soheilipour F; Dalili S; Kharazmi H; Didban A; Akhlaghi A; Ghaznavi S; Shahbazi M
    Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38682328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
    Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
    J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial.
    Czepielewski MA; Garret Q; Vencio SAC; Rassi N; Faria MS; Senn CCP; Bronstein MD; Cerqueira MJAG; Neves ACL; Spinola-Castro AM; Cunha MPR; Leite NR; Wassermann GE; Alegria MC; Toffoletto O; Afiune J; Baradelli R; Rodrigues DG; Scharf M
    Growth Horm IGF Res; 2021 Feb; 56():101372. PubMed ID: 33260063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
    Deal CL; Steelman J; Vlachopapadopoulou E; Stawerska R; Silverman LA; Phillip M; Kim HS; Ko C; Malievskiy O; Cara JF; Roland CL; Taylor CT; Valluri SR; Wajnrajch MP; Pastrak A; Miller BS
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2717-e2728. PubMed ID: 35405011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial.
    Czepielewski MA; Garret Q; Vencio SAC; Rassi N; Felicio JS; Faria MS; Senn CCP; Bronstein MD; Cerqueira MJAG; Neves ACL; Sgarbi JA; Spinola-Castro AM; Cunha MPR; Bandeira F; Toffoletto O; Afiune J; Baradelli R; Rodrigues DG; Scharf M
    Growth Horm IGF Res; 2019; 48-49():29-35. PubMed ID: 31493626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Samtropin™ recombinant human growth hormone; a double-blind randomized clinical trial.
    Tabatabaei-Malazy O; Mohajeri-Tehrani MR; Heshmat R; Taheri E; Shafiee G; Razzaghy-Azar M; Rabbani A; Qorbani M; Adibi H; Shahbazi S; Karimi F; Rezaian S; Larijani B
    J Diabetes Metab Disord; 2014; 13(1):115. PubMed ID: 25648850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.
    Borrás Pérez V; López-Siguero JP; Martínez G; Corripio R; Fernández JM; Labarta JI; Ferrer M; Cabrinety N; Prieto P; Ramón-Krauel M; Bosch J; Espino R; Palla Garcia M; Rebollo FJ
    Adv Ther; 2015 Feb; 32(2):148-56. PubMed ID: 25667132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
    Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.
    Horikawa R; Tanaka T; Hasegawa Y; Yorifuji T; Ng D; Rosenfeld RG; Hoshino Y; Okayama A; Shima D; Gomez R; Pastrak A; Castellanos O
    Horm Res Paediatr; 2022; 95(3):275-285. PubMed ID: 35417909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency.
    Peterkova V; Arslanoglu I; Bolshova-Zubkovskaya E; Romer T; Zdravkovic D; Kratzsch J; Ji HJ; Savoy C; Saenger P
    Horm Res; 2007; 68(6):288-93. PubMed ID: 17627092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
    Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study.
    Jiang Z; Chen X; Dong G; Lou Y; Zhang J; Cheng X; Pan J; Liao W; Wu J; Huang X; Jin X; Liu D; Zeng T; Zhu S; Dong Q; Luo X; Lan D; Cao L; Zhang X; Liu J; Dai M; Zhang M; Liu L; Dong J; Zhao D; Ni S; Fu J
    Front Pharmacol; 2022; 13():955809. PubMed ID: 36034802
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Biosimilar Growth Hormone in Indian Children.
    Khadilkar V; Ekbote V; Khadilkar A; Maheshwari A
    Indian J Endocrinol Metab; 2018; 22(4):525-529. PubMed ID: 30148102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Effectiveness and Comparable Safety in Biweekly
    Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
    Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
    Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
    BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X; Hou L; Liang L; Dong G; Shen S; Zhao Z; Gong CX; Li Y; Du ML; Su Z; Du H; Yan C
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM
    Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and patient satisfaction of norditropin and sogroya in patients with growth hormone deficiency: a systematic review and meta-analysis of randomized controlled trials.
    Altobaishat O; Abouzid M; Moawad MHED; Sharaf A; Al-Ajlouni Y; Umar TP; Bani-Salameh A; Tanashat M; Bataineh OA; Nashwan AJ
    Endocrine; 2024 Apr; ():. PubMed ID: 38658475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.